Latest Breaking News On - Gamma deltat cell engager - Page 4 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business . Shattuck Labs, Inc.March 15, 2021 GMT – Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 (PD1-Fc-OX40L), expected in the second half of 2021 – AUSTIN, TX and DURHAM, NC, March 15, 2021 (GLOBE NEWSWIRE) Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK ), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided r

United statesNorth carolinaStephanie ascherConor richardsonTaylor schreiberPreclinical developmentStern investor relations incSociety for immunotherapy of cancerTakeda pharmaceuticalsExchange commissionDevelopment rd expensesAmerican association for cancer researchShattuck labs incTruist securities life sciences summitAgonist redirected checkpointChief executive officer